Similar results also were found that M2 marker MRC1 expression was dramatically increased in Lon-overexpressing B16/F10 tumor and decreased under the treatment with Fc-VFD and/or anti-PD-L1 (Fig. 2H), and Fc-VFD induced the M1-type of THP-1 and the treatment with the M2 inducer and the Lon-overexpressing cancer C.M. as negative controls (Fig. 4G). The gene discussed is MRC1; the disease is cancer.